Literature DB >> 29725820

CADASIL brain vessels show a HTRA1 loss-of-function profile.

Andreas Zellner1, Eva Scharrer1, Thomas Arzberger2,3, Chio Oka4, Valérie Domenga-Denier5,6, Anne Joutel5,6, Stefan F Lichtenthaler7,8,9,10, Stephan A Müller7,8, Martin Dichgans1,10, Christof Haffner11.   

Abstract

Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) and a phenotypically similar recessive condition (CARASIL) have emerged as important genetic model diseases for studying the molecular pathomechanisms of cerebral small vessel disease (SVD). CADASIL, the most frequent and intensely explored monogenic SVD, is characterized by a severe pathology in the cerebral vasculature including the mutation-induced aggregation of the Notch3 extracellular domain (Notch3ECD) and the formation of protein deposits of insufficiently determined composition in vessel walls. To identify key molecules and pathways involved in this process, we quantitatively determined the brain vessel proteome from CADASIL patient and control autopsy samples (n = 6 for each group), obtaining 95 proteins with significantly increased abundance. Intriguingly, high-temperature requirement protein A1 (HTRA1), the extracellular protease mutated in CARASIL, was found to be strongly enriched (4.9-fold, p = 1.6 × 10-3) and to colocalize with Notch3ECD deposits in patient vessels suggesting a sequestration process. Furthermore, the presence of increased levels of several HTRA1 substrates in the CADASIL proteome was compatible with their reduced degradation as consequence of a loss of HTRA1 activity. Indeed, a comparison with the brain vessel proteome of HTRA1 knockout mice (n = 5) revealed a highly significant overlap of 18 enriched proteins (p = 2.2 × 10-16), primarily representing secreted and extracellular matrix factors. Several of them were shown to be processed by HTRA1 in an in vitro proteolysis assay identifying them as novel substrates. Our study provides evidence for a loss of HTRA1 function as a critical step in the development of CADASIL pathology linking the molecular mechanisms of two distinct SVD forms.

Entities:  

Keywords:  CADASIL; CARASIL; Cerebral small vessel disease; Extracellular matrix; HTRA1; Proteomics

Mesh:

Substances:

Year:  2018        PMID: 29725820     DOI: 10.1007/s00401-018-1853-8

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  21 in total

1.  Candesartan prevents arteriopathy progression in cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy model.

Authors:  Taisuke Kato; Ri-Ichiroh Manabe; Hironaka Igarashi; Fuyuki Kametani; Sachiko Hirokawa; Yumi Sekine; Natsumi Fujita; Satoshi Saito; Yusuke Kawashima; Yuya Hatano; Shoichiro Ando; Hiroaki Nozaki; Akihiro Sugai; Masahiro Uemura; Masaki Fukunaga; Toshiya Sato; Akihide Koyama; Rie Saito; Atsushi Sugie; Yasuko Toyoshima; Hirotoshi Kawata; Shigeo Murayama; Masaki Matsumoto; Akiyoshi Kakita; Masato Hasegawa; Masafumi Ihara; Masato Kanazawa; Masatoyo Nishizawa; Shoji Tsuji; Osamu Onodera
Journal:  J Clin Invest       Date:  2021-11-15       Impact factor: 14.808

2.  Long non-coding RNA lincRNA-erythroid prosurvival (EPS) alleviates cerebral ischemia/reperfusion injury by maintaining high-temperature requirement protein A1 (Htra1) stability through recruiting heterogeneous nuclear ribonucleoprotein L (HNRNPL).

Authors:  Haifeng Guo; Xia Guo; Shiting Jiang
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

3.  Whole-exome sequencing reveals a role of HTRA1 and EGFL8 in brain white matter hyperintensities.

Authors:  Rainer Malik; Nathalie Beaufort; Simon Frerich; Benno Gesierich; Marios K Georgakis; Kristiina Rannikmäe; Amy C Ferguson; Christof Haffner; Matthew Traylor; Michael Ehrmann; Cathie L M Sudlow; Martin Dichgans
Journal:  Brain       Date:  2021-10-22       Impact factor: 15.255

Review 4.  CADASIL from Bench to Bedside: Disease Models and Novel Therapeutic Approaches.

Authors:  Arianna Manini; Leonardo Pantoni
Journal:  Mol Neurobiol       Date:  2021-01-19       Impact factor: 5.590

Review 5.  NF-κB signalling pathways in nucleus pulposus cell function and intervertebral disc degeneration.

Authors:  Guang-Zhi Zhang; Ming-Qiang Liu; Hai-Wei Chen; Zuo-Long Wu; Yi-Cheng Gao; Zhan-Jun Ma; Xue-Gang He; Xue-Wen Kang
Journal:  Cell Prolif       Date:  2021-05-24       Impact factor: 6.831

6.  Novel mutation in HTRA1 in a family with diffuse white matter lesions and inflammatory features.

Authors:  Amin Ziaei; Xiaohong Xu; Leila Dehghani; Carine Bonnard; Andreas Zellner; Alvin Yu Jin Ng; Sumanty Tohari; Byrappa Venkatesh; Christof Haffner; Bruno Reversade; Vahid Shaygannejad; Mahmoud A Pouladi
Journal:  Neurol Genet       Date:  2019-07-08

Review 7.  PIP2: A critical regulator of vascular ion channels hiding in plain sight.

Authors:  Osama F Harraz; David Hill-Eubanks; Mark T Nelson
Journal:  Proc Natl Acad Sci U S A       Date:  2020-08-06       Impact factor: 11.205

Review 8.  Overlapping Protein Accumulation Profiles of CADASIL and CAA: Is There a Common Mechanism Driving Cerebral Small-Vessel Disease?

Authors:  Kelly Z Young; Gang Xu; Simon G Keep; Jimo Borjigin; Michael M Wang
Journal:  Am J Pathol       Date:  2020-12-30       Impact factor: 4.307

Review 9.  Modeling blood-brain barrier pathology in cerebrovascular disease in vitro: current and future paradigms.

Authors:  Anuska V Andjelkovic; Svetlana M Stamatovic; Chelsea M Phillips; Gabriela Martinez-Revollar; Richard F Keep
Journal:  Fluids Barriers CNS       Date:  2020-07-16

10.  Human iPS cell-derived mural cells as an in vitro model of hereditary cerebral small vessel disease.

Authors:  Yumi Yamamoto; Katsutoshi Kojima; Daisuke Taura; Masakatsu Sone; Kazuo Washida; Naohiro Egawa; Takayuki Kondo; Eiko N Minakawa; Kayoko Tsukita; Takako Enami; Hidekazu Tomimoto; Toshiki Mizuno; Raj N Kalaria; Nobuya Inagaki; Ryosuke Takahashi; Mariko Harada-Shiba; Masafumi Ihara; Haruhisa Inoue
Journal:  Mol Brain       Date:  2020-03-19       Impact factor: 4.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.